Search research articles
Contact Us
Filters
Showing results (371-380 of 498) with videos related to
Page
of 50
Sort By:
JAMA Oncology
|
January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review
Rachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
Biorxiv : the Preprint Server for Biology
|
June 3, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Xiaozhuo Liu, Eduardo Cortes, Yibing Ji, et al.
European Urology Oncology
|
November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials
Krishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas
Shuang G Zhao, William S Chen, Rajdeep Das, et al.
JCI Insight
|
November 3, 2018
Transcriptomic heterogeneity in multifocal prostate cancer
Simpa S Salami, Daniel H Hovelson, Jeremy B Kaplan, et al.
European Urology
|
February 11, 2026
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Paul L Nguyen, Marisa A Kollmeier, Dana E Rathkopf, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 15, 2021
TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma
Xiao-Ming Wang, Yuping Zhang, Rahul Mannan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 6, 2019
Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy
Naomi Y Jiang, Audrey T Dang, Ye Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie, Meredith M Regan, Marc Buyse, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer
Amy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.
Page
of 50
Search research articles
Search
Showing results (371-380 of 498) with videos related to
Sort By:
Page
of 50
JAMA Oncology
|
January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review
Rachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
Biorxiv : the Preprint Server for Biology
|
June 3, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Xiaozhuo Liu, Eduardo Cortes, Yibing Ji, et al.
European Urology Oncology
|
November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials
Krishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas
Shuang G Zhao, William S Chen, Rajdeep Das, et al.
JCI Insight
|
November 3, 2018
Transcriptomic heterogeneity in multifocal prostate cancer
Simpa S Salami, Daniel H Hovelson, Jeremy B Kaplan, et al.
European Urology
|
February 11, 2026
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Paul L Nguyen, Marisa A Kollmeier, Dana E Rathkopf, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 15, 2021
TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma
Xiao-Ming Wang, Yuping Zhang, Rahul Mannan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 6, 2019
Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy
Naomi Y Jiang, Audrey T Dang, Ye Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie, Meredith M Regan, Marc Buyse, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer
Amy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.
Page
of 50